Global Oncology Academy

How New Therapies & Patient Characteristics Guide cGVHD Treatment Sequencing

ReachMD Healthcare Image

Here’s how you can use new FDA-approved therapies and patient characteristics to guide treatment sequencing for steroid-refractory chronic GVHD.

  • Overview

    Until recently, there were no approved therapeutic options for patients with steroid-refractory chronic graft versus host disease (cGVHD). But with the FDA approval of ibrutinib, ruxolitinib, and belumosudil, we can use these new therapies and a patient’s characteristics to guide treatment sequencing decisions in the second-line setting, ensuring optimal outcomes. Learn more with Dr. Charles Turck and Dr. Doris Ponce, Associate Attending Physician and Director of the GVHD Program (Adult BMT) at Memorial Sloan Kettering Cancer Center in New York City.

Facebook Comments



We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free